---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-140700"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:37:05.521921+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Joel S. Marcus resigns from Frequency Therapeutics board effective May 5, 2023

## Summary
- Joel S. Marcus resigned from the Board of Directors and all committees on May 5, 2023.
- Resignation was immediately effective as of that date.
- Mr. Marcus confirmed his departure was not due to any disagreement with the company.

## SEC filing metadata
- accession: 0001193125-23-140700
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312523140700/0001193125-23-140700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312523140700/d471290d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-140700
- JSON: https://secwatch.observer/filing/0001193125-23-140700.json
- Plain text: https://secwatch.observer/filing/0001193125-23-140700.txt

## Key facts
- Executive change
  Joel S. Marcus resigned as Director at Korro Bio, Inc..
  - Action: resigned
  - Role: Director
  source text: On May 5, 2023, Joel S. Marcus notified Frequency Therapeutics, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”) and all committees of the Board on which he served, which was immediately effective.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312523140700/0001193125-23-140700-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.